2007 Standards, Options, and Recommendations: Use of erythropoiesis- stimulating agents (ESA: Epoetin alfa, epoetin beta, and darbepoetin) for the management of anemia in children with cancer

Pediatric Blood and Cancer

Volumn 53, Issue 1, 2009, Pages 7-12

  Marec Berard, Perrine ^a   Chastagner, Pascal ^b   Kassab Chahmi, Diana ^c   Casadevall, Nicole ^d   Marchal, Christian ^e   Misset, Jean Louis ^f   Ray Coquard, Isabelle ^g  

^a Hemato Oncologic Pediatric Institute   (France)

^b Department of Hemato Oncologic Pediatrics   (France)

^c French National Cancer Institute   (France)

^d HÔPITAL SAINT ANTOINE   (France)

^e Alexis Vautrin Cancer Center   (France)

^f SAINT LOUIS HOSPITAL   (France)

^g CENTRE LÉON BÉRARD   (France)

Author keywords

Anemia; Cancer; Children; Clinical practice guidelines; Epoetin; ESA

Indexed keywords

ANTIANEMIC AGENT; GRANULOCYTE COLONY STIMULATING FACTOR; HEMOGLOBIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN; DRUG DERIVATIVE; ERYTHROPOIETIN; ERYTHROPOIETIN RECEPTOR;

ANEMIA; CLINICAL PRACTICE; HEMOGLOBIN BLOOD LEVEL; HUMAN; MEDICAL INFORMATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; THROMBOEMBOLISM; ANIMAL; CELL PROLIFERATION; CHILD; DRUG EFFECT; INTRAVENOUS DRUG ADMINISTRATION; METABOLISM; MORTALITY; NEOPLASM; PATHOLOGY; SURVIVAL RATE;

ANEMIA; ANIMALS; CELL PROLIFERATION; CHILD; EPOETIN ALFA; ERYTHROPOIETIN; ERYTHROPOIETIN, RECOMBINANT; HEMATINICS; HUMANS; INJECTIONS, INTRAVENOUS; NEOPLASMS; PRACTICE GUIDELINES AS TOPIC; QUALITY OF LIFE; RECEPTORS, ERYTHROPOIETIN; SURVIVAL RATE;

EID: 66149087724     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.21953     Document Type: Review

References (25)

1. Fervers B, Hardy J, Blanc-Vincent MP, et al. SOR: Project methodology. Br J Cancer 2001;84:8-16. (Pubitemid 32522119)
2. Agree C. Development and validation of an international appraisal instrument for assessing the quality of clinical practice guidelines: The AGREE project. Qual Saf Health Care 2003;12:18-23. (Pubitemid 36241251)
3. Spaeth D, Marchal C, Blanc-Vincent MP. Standards, Options, and Recommendations for using erythropoietin in cancerology. Bull Cancer 1998;85:337-346.
4. Spaeth D, Marchal C, Bataillard A, et al. Updating 1999 of Standards, Options and Recommendations (SOR) for the clinical use of erythropoietin in oncology. Federation of The French Cancer Centres (FNCLCC). Bull Cancer 1999;86:631-639.
5. Spaeth D, Casadevall N, Daouphars M, et al. Summary version of the Standards, Options and Recommendations for the use of recombinant erythropoietin (epoietin-alpha and beta, darbepoietin- alpha, EPO) in the management of anaemia in oncology - Update 2003. Bull Cancer 2004;91:179-188.
6. Bolonaki I, Stiakaki E, Lydaki E, et al. Treatment with recombinant human erythropoietin in children with malignancies. Pediatr Hematol Oncol 1996;13:111-121. (Pubitemid 26091750)
7. Leon P, Jimenez M, Barona P, et al. Recombinant human erythropoietin for the treatment of anemia in children with solid malignant tumors. Med Pediatr Oncol 1998;30:110-116. (Pubitemid 128765926)
8. Csaki C, Ferencz T, Schuler D, et al. Recombinant human erythropoietin in the prevention of chemotherapy-induced anaemia in children with malignant solid tumours. Eur J Cancer 1998; 34:364-367. (Pubitemid 28183835)
9. Henze G, Michon J, Morland B, et al. Phase III randomized study: Efficacy of epoetin alfa in reducing blood transfusions in newly diagnosed pediatric cancer patients receiving chemotherapy. Am Soc Clin Oncol 2002 (Abstr 1547).
10. Buyukpamukcu M, Varan A, Kutluk T, et al. Is epoetin alfa a treatment option for chemotherapy-related anemia in children? Med Pediatr Oncol 2002;39:455-458.
11. Razzouk BI, Hord JD, Hockenberry M, et al. Double-blind, placebo-controlled study of quality of life, hematologic end points, and safety of weekly epoetin alfa in children with cancer receiving myelosuppressive chemotherapy. J Clin Oncol 2006;24:3583-3589. (Pubitemid 46630530)
12. Wagner LM, Billups CA, Furman WL, et al. Combined use of erythropoietin and granulocyte colony-stimulating factor does not decrease blood transfusion requirements during induction therapy for high-risk neuroblastoma: A randomized controlled trial. J Clin Oncol 2004;22:1886-1893. (Pubitemid 41095180)
13. Hinds PS, Hockenberry M, Feusner J, et al. Hemoglobin response and improvements in quality of life in anemic children with cancer receiving myelosuppressive chemotherapy. J Support Oncol 2005; 3:10-11. (Pubitemid 43256768)
14. Rizzo JD, Somerfield MR, Hagerty KL, et al. Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update. J Clin Oncol 2008;26:132-149.
15. Acs G, Acs P, Beckwith SM, et al. Erythropoietin and erythropoietin receptor expression in human cancer. Cancer Res 2001; 61:3561-3565. (Pubitemid 32694960)
16. Leo C, Horn LC, Rauscher C, et al. Expression of erythropoietin and erythropoietin receptor in cervical cancer and relationship to survival, hypoxia, and apoptosis. Clin Cancer Res 2006;12:6894-6900. (Pubitemid 44974481)
17. Longmore GD. Do cancer cells express functional erythropoietin receptors? N Engl J Med 2007;356:2447.
18. Elliott S, Busse L, Bass MB, et al. Anti-Epo receptor antibodies do not predict Epo receptor expression. Blood 2006;107:1892-1895. (Pubitemid 43289368)
19. Brown WM, Maxwell P, Graham AN, et al. Erythropoietin receptor expression in non-small cell lung carcinoma: A question of antibody specificity. Stem Cells 2007;25:718-722. (Pubitemid 46354231)
20. Osterborg A, Aapro M, Cornes P, et al. Preclinical studies of erythropoietin receptor expression in tumour cells: Impact on clinical use of erythropoietic proteins to correct cancer-related anaemia. Eur J Cancer 2007;43:510-519. (Pubitemid 46177584)
21. Yasuda Y, Fujita Y, Matsuo T, et al. Erythropoietin regulates tumour growth of human malignancies. Carcinogenesis 2003;24:1021-1029. (Pubitemid 36833185)
22. Farrell F, Lee A. The erythropoietin receptor and its expression in tumor cells and other tissues. Oncologist 2004;9:18-30. (Pubitemid 39658342)
23. Sinclair AM, Todd MD, Forsythe K, et al. Expression and function of erythropoietin receptors in tumors: Implications for the use of erythropoiesis-stimulating agents in cancer patients. Cancer 2007; 110:477-488.
24. Sartelet H, Fabre M, Castaing M, et al. Expression of erythropoietin and its receptor in neuroblastomas. Cancer 2007;110:1096-1106. (Pubitemid 47312876)
25. Batra S, Perelman N, Luck LR, et al. Pediatric tumor cells express erythropoietin and a functional erythropoietin receptor that promotes angiogenesis and tumor cell survival. Lab Invest 2003; 83:1477-1487. (Pubitemid 37267831)